LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

ACCELERATE FAIR Initiative Letter of Support

19/06/2020
POSITION PAPER

ACCELERATE FAIR Initiative Letter of Support

June 19, 2020

• Professor Gilles Vassal, ACCELERATE Chair and Innovative Therapies for Children with Cancer in Europe (ITCC) President

• Dr. Nathalie Gaspar, ACCELERATE Fostering Age Inclusive Research (FAIR) Working Group Co-Chair

• Chris Copland, ACCELERATE Fostering Age Inclusive Research (FAIR) Working Group Co-Chair

RE: Fostering Age-Inclusive Research (FAIR) Trials Initiative

Dear Professor Vassal, Dr. Gaspar, and Mr. Copland,

The Biotechnology Innovation Organization (BIO), European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), European Federation of Pharmaceutical Industries and Associations (EFPIA), EuropaBio – the EuropaBio Association of Bioindustries, the Pharmaceutical Research Manufacturers of America (PhRMA), and our members recognise and value the efforts led by the ACCELERATE’S FAIR Initiative. With the goal of facilitating timely access to novel therapies for children with cancer, we see the FAIR Initiative as an important step to encourage researchers, regulators, ethics committees, and health technology assessment bodies to support and consider the systematic inclusion of adolescents (i.e., individuals from 12 to below 18 years of age), in oncology studies based on the benefit-risk profile of a product, when scientifically, ethically justified and feasible.

Together the Biotechnology Innovation Organization (BIO), European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), European Federation of Pharmaceutical Industries and Associations (EFPIA), EuropaBio – the EuropaBio Association of Bioindustries, Pharmaceutical Research Manufacturers of America (PhRMA), representing the world’s leading biotechnology and biopharmaceutical companies and related organisations, we want to bring innovative treatments to all patients that need them and encourage researchers, regulators, ethics committees, and health technology assessment bodies to recognise the use of flexible and practical innovative approaches so that new medicines can reach patients as soon as possible. We encourage an open dialogue between authoritative bodies and companies on timely development strategies for paediatric populations (e.g. inclusion of adolescents in adult studies, or conducting adolescent studies concurrent to adult studies, where scientifically and ethically justified and feasible).

We do appreciate the efforts led by the FAIR Initiative and hope to continue to partner with ACCELERATE to speed up the delivery of innovative therapies to children and adolescents.

E. Cartier Esham, Ph.D.
Executive Vice President, Emerging Companies
Senior Vice President, Science and Regulatory
Biotechnology Innovation Organization (BIO)

Magda Chlebus
Executive Director
Science policy & Regulatory Affairs
EFPIA

Alexander Natz
EUCOPE Secretary General
Chief Medical Officer and Executive Vice President, Science and Regulatory Advocacy
PhRMA

Bernard Grimm
Healthcare Director
EuropaBio

ACCELERATE FAIR Initiative Letter of Support


Download
2020_06_H_PP_ACCELERATE_FAIR-Initiative_Letter-of-SupportDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

21/05/2025

Ensuring Biotech Integration in the Single Market


Read more
16/04/2025

EuropaBio position on the EU Life Sciences Strategy


Read more
08/04/2025

EFIB 2025 Brussels Statement


Read more

Important links

  • Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World
  • Ensuring Biotech Integration in the Single Market

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.